Accu-Chek partners with Mylestone Health to enhance iPhone app, Web site
INDIANAPOLIS Roche Diabetes Care, the maker of the Accu-Chek line of blood glucose meters and insulin delivery systems, has partnered with Mylestone Health, the developer of Glucose Buddy and its related Web site, www.glucosebuddy.com, to enhance the capabilities of Roche’s iPhone app.
The new version of Glucose Buddy iPhone app and Web site now both include Accu-Chek Testing in Pairs, an easy-to-use tool that shows the before-and-after effects of meals, activities and other specific events on your blood glucose levels. It is designed for use when you want to focus on one thing in your daily eating habits or routine.
“We are so pleased to be joining forces with Mylestone Health to offer our Testing in Pairs tool as part of its already highly successful iPhone app Glucose Buddy,” said Roche VP marketing Dan Kane. “We believe with the addition of the new Accu-Chek Testing in Pairs tool, people with diabetes will feel empowered and motivated to make changes based on the simplicity of the tool and the ability to personalize the experience.
“We recognized Mylestone as a company that already has relationships with thousands of Glucose Buddy users on an innovative platform, and we have a useful tool to offer people with diabetes that can help them take the self-management of their condition a step or two further,” Kane added.
GSK withdraws regulatory application for additional use of Avodart
LONDON British drug maker GlaxoSmithKline is temporarily withdrawing its regulatory approval application seeking an additional use for an enlarged prostate treatment in order to update it, the company announced Monday.
The company is seeking approval from the Food and Drug Administration of Avodart (dutasteride) for prostate cancer risk reduction in men who have increased risk of developing the disease. The drug is currently approved for treating enlarged prostate.
GSK did not specify what it would add to the application, but said the updates were not related to new safety or efficacy findings and that it would resubmit the application “shortly.”
Save Flexible Spending Plans lobbying FSA reform
NEW YORK The simple fact is that healthcare reform in this country has to be paid for somehow. But cutting OTCs out of FSAs amounts to an additional healthcare tax levied against Americans actually trying to save money on health care today. That’s just backward thinking.
When you consider that allowing thrifty Americans to buy an OTC allergy medication with pre-tax funds may dissuade them from buying a generic Rx-only allergy medication for the cheaper co-pay. And while those Rx-allergy users are taking care of their generic co-pay, who’s picking up on the cost of the rest of the medicine?
Approximately 14.8% of American households have an FSA account, according to the National Center for Health Statistics, which means that some 16.5 million families are saving pre-tax income dollars. The Senate shouldn’t be looking to cut this healthcare savings a la tax benefit; they should be trying to figure out how to get more Americans turned onto FSA savings.